Inflammatory Bowel Disease Research Program
The Inflammatory Bowel Disease Research Program at NYU Langone Health bridges basic, clinical, and educational disciplines and brings together faculty who build on the breadth of our immunology, microbiology, and cell biology research to foster cross-disciplinary collaborations and studies. Our mission is to build on our institution’s tradition of turning basic science discoveries into treatments for inflammatory bowel diseases (IBD) including Crohn’s disease and ulcerative colitis.
Following their research on immune signaling molecules, NYU Langone microbiologists worked with pharmaceutical companies to develop the drug infliximab, which blocks one such molecule called TNF-α. It remains among the most commonly used therapies for IBD.
Faculty at the Inflammatory Bowel Disease Research Program work hand-in-hand with gastroenterologists and surgeons at NYU Langone’s clinical Inflammatory Bowel Disease Center with the goal of discovering new treatment strategies and how best to apply them to improve patient care.
Ken H. Cadwell, PhD, the Recanati Family Professor of Microbiology and professor in the Departments of Microbiology and Medicine is our program director. Dr. Cadwell is recognized for his research on how our immune system is regulated by the diverse microbes we encounter throughout our lives. His discoveries have contributed to our understanding of how imbalances in our relationship with microbes in the gut can lead to inflammation, as seen in patients with IBD.
Dr. Cadwell works together with other members of the leadership team to integrate basic and clinical research with training objectives of the Inflammatory Bowel Disease Research Program. Jordan E. Axelrad, MD, MPH, directs our clinical and translational inflammatory bowel disease research efforts and oversees the gastrointestinal diseases biorepository. Dr. Axelrad is recognized for his research on malignant and infectious complications of IBD, specifically, in elucidating how exposures such as gastrointestinal infections may complicate IBD or trigger it to develop.
David P. Hudesman, MD, and Feza Remzi, MD, are co-directors of our Inflammatory Bowel Disease Center. Together with Dr. Cadwell and Dr. Axelrad, they manage IBD research studies and clinical trials representing partnerships among clinicians, scientists, and industry.
We are hiring research scientists to join our team. Learn more about our available positions.
Select Faculty Publications
Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin
Cancer cell. 2023 Sep 11; 41:1567-1585.e7
Proteogenomic insights suggest druggable pathways in endometrial carcinoma
Cancer cell. 2023 Sep 11; 41:1586-1605.e15
Cis-regulatory arbitrators of regeneration
Cell stem cell. 2023 Sep 06;
Single-Cell Analysis of CX3CR1+ Cells Reveals a Pathogenic Role for BIRC5+ Myeloid Proliferating Cells Driven by Staphylococcus aureus Leukotoxins
Journal of immunology (1950). 2023 Sep 01; 211:836-843
Suboptimal Guideline Adherence and Biomarker Underutilization in Monitoring of Post-operative Crohn's Disease
Digestive diseases and sciences. 2023 Sep ; 68:3596-3604
Endolysin inhibits skin colonization by patient-derived Staphylococcus aureus and malignant T cell activation in cutaneous T cell lymphoma
Journal of investigative dermatology. 2023 Sep ; 143:1757-1768.e3
Structured versus non-structured reporting of pelvic MRI for ileal pouch evaluation: clarity and effectiveness
Abdominal radiology. 2023 Sep ; 48:2978-2985
Preoperative Risk Factors for Adverse Events in Adults Undergoing Bowel Resection for Inflammatory Bowel Disease: 15-Year Assessment of ACS-NSQIP
American journal of gastroenterology. 2023 Aug 25;